TY - JOUR
T1 - Clonal Hematopoiesis
T2 - A new layer in the liquid biopsy story in lung cancer
AU - Bauml, Joshua
AU - Levy, Benjamin
N1 - Funding Information:
J. Bauml reports receiving commercial research grants from Bayer, Carevive Systems, Janssen, Merck, and Novartis, other commercial research support from Incyte, and is a consultant/advisory board member for AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, and Guardant Health. B. Levy reports receiving commercial research grants from Boehringer Ingelheim and Celgene and is a consultant/advisory board member for Admera Health, AstraZeneca, Celgene, Eli Lilly, Genentech, Merck, and Takeda.
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/9/15
Y1 - 2018/9/15
N2 - Cell-free DNA (cfDNA) is a unique biospecimen that contains multiple sources of DNA, including tumor, germline, fetal, and others. Clonal hematopoiesis, a process that leads to expansion of mutations in peripheral blood cells, is an additional source of DNA that adds a layer of complexity when interpreting results.
AB - Cell-free DNA (cfDNA) is a unique biospecimen that contains multiple sources of DNA, including tumor, germline, fetal, and others. Clonal hematopoiesis, a process that leads to expansion of mutations in peripheral blood cells, is an additional source of DNA that adds a layer of complexity when interpreting results.
UR - http://www.scopus.com/inward/record.url?scp=85053204071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053204071&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-0969
DO - 10.1158/1078-0432.CCR-18-0969
M3 - Article
C2 - 29748181
AN - SCOPUS:85053204071
SN - 1078-0432
VL - 24
SP - 4352
EP - 4354
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 18
ER -